Skip to main content

Poolbeg Pharma upbeat on preliminary influenza drug results

ⓘ This article is third-party content and does not represent the views of this site. We make no guarantees regarding its accuracy or completeness.

--News Direct--

Poolbeg Pharma PLC (OTCQB:POLBF) CEO Jeremy Skillington speaks to Proactive after announcing initial data analysis, including a 'clear dose-related response', for its drug, POLB 001, a potential treatment for severe influenza. Skillington says the 'early data readout' indicates that the challenge trial was successful.

Contact Details

Proactive UK Ltd

+44 20 7989 0813

uk@proactiveinvestors.com

View source version on newsdirect.com: https://newsdirect.com/news/poolbeg-pharma-upbeat-on-preliminary-influenza-drug-results-758545326

Report this content

If you believe this article contains misleading, harmful, or spam content, please let us know.

Report this article

Recent Quotes

View More
Symbol Price Change (%)
AMZN  272.65
-4.77 (-1.72%)
AAPL  311.00
+1.62 (0.52%)
AMD  482.05
-36.53 (-7.04%)
BAC  63.25
+0.35 (0.56%)
GOOG  360.13
-15.22 (-4.05%)
META  588.77
+0.83 (0.14%)
MSFT  487.46
-5.35 (-1.09%)
NVDA  219.22
+7.28 (3.43%)
ORCL  144.39
-1.35 (-0.93%)
TSLA  321.55
-5.80 (-1.77%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.